Inhibition of Ehrlich ascites carcinoma by *Manilkara zapota* L. stem bark in Swiss albino mice

M Abu Osman, M Mamunur Rashid, M Abdul Aziz, M Rowshahul Habib, M Rezaul Karim*

Department of Biochemistry and Molecular Biology, Faculty of Science, Rajshahi University, Rajshahi-6205, Bangladesh

**ARTICLE INFO**

*Article history:* Received 15 March 2011 Received in revised form 15 April 2011 Accepted 7 May 2011 Available online 20 May 2011

**Keywords:** *Manilkara zapota*  Antitumour activity  Stem bark  Ehrlich ascites carcinoma  Haematological parameter

**ABSTRACT**

**Objective:** To evaluate the antitumor activity of *Manilkara zapota* (*M. zapota*) L. stem bark against Ehrlich ascites carcinoma (EAC) in Swiss albino mice. **Methods:** The *in vivo* antitumour activity of the ethyl acetate extract of stem bark of *M. zapota* L. (EASM) was evaluated at 50, 100 and 200 mg/kg bw against EAC using mean survival time. After administration of the extract of *M. zapota*, viable EAC cell count and body weight in the EAC tumour hosts were observed. The animal was also observed for improvement in the haematological parameters (*e.g.*, haemoglobin content, red and white blood cells count and differential cell count) after EASM treatment. **Results:** Intraperitoneal administration of EASM reduced viable EAC cells, increased the survival time, and restored altered haematological parameters. Significant efficacy was observed for EASM at 100 mg/kg dose (*P*<0.05). **Conclusions:** It can be concluded that the ethyl acetate extract of stem bark of *M. zapota* L. possesses significant antitumour activity.

1. Introduction

The majority of the world’s population in developing countries still relies on herbal medicines to meet their health needs in cases when synthetic medicine could not relieve patients who suffer from painful illnesses like cancer[1]. In the modern system of medicine, several chemotherapeutic agents have been developed as a result of screening of the medicinal plants in various parts of the world[2]. So there is a growing interest in the pharmacological evaluation of medicinal plants.

*Manilkara zapota* (*M. zapota*) (L.) P. Royen, which belongs to the family Sapotaceae, is an evergreen, glabrous tree, 8–15 m in height. It is cultivated throughout Indian subcontinent including Bangladesh, though it is native to Mexico and Central America[3]. The seeds of *M. zapota* are aperients, diuretic tonic and febrifuge. Stem bark is astringent and febrifuge[4]. The leaves and bark are used to treat cough, cold, dysentery and diarrhoea[5].

Antimicrobial and antioxidant activities are also reported from the leaves of *M. zapota*[6,7]. The major constituents isolated from fruits of *M. zapota* are polyphenols (methyl chlorogenate, dihydromyricetin, quercitrin, myricitrin, (+)-catechin, (-)-epicatechin, (+)-gallocatechin, and gallic acid)[8]. However, no studies to date have been conducted to demonstrate the antitumour activity of *M. zapota*. The present study was carried out to evaluate the *in vivo* antitumour activity of ethyl acetate extract of the stem bark of *M. zapota* (EASM) against Ehrlich ascites carcinoma (EAC) in mice.

2. Materials and methods

2.1. Plant materials

Stem bark of *M. zapota* (Family: Sapotaceae) were collected in August, 2010 from Rajshahi district of Bangladesh. The plant material was taxonomically identified by Professor ATM Naderuzzaman, Department of Botany, University of Rajshahi and a voucher specimen was deposited under the accession number DACB–23801 at the Bangladesh National
2.2. Extraction

The collected stem bark were cleaned and shade-dried. The dried bark were then pulverized into a coarse powder by a grinding machine (FFC-15, China). The powdered stem bark (450 g) were extracted with ethyl acetate at room temperature. These two extracts were then filtered through filter papers and filtrates were evaporated under reduced pressure at 40 °C using a rotary evaporator to get 5.5 g EASM.

2.3. Animals

Male Swiss albino mice (25–30 g) were procured from the Animal Research Branch of the International Centre for Diarrhoeal Diseases and Research, Bangladesh (ICDDRB). They were used throughout the study and housed in iron cages in a controlled environment [temperature (25±2) °C and 12 h dark/light cycle] with standard laboratory diet and water ad libitum. Experiments were carried out in accordance with the Ethical Committee Guidelines laid down by the local committee regarding the care and use of animals for experimental procedures.

2.4. Tumour cells

EAC cells were obtained from the Courtesy of Indian Institute for Chemical Biology (IICB), Kolkata, India and maintained by weekly intraperitoneal (ip) inoculation of 10⁶ cells/mouse in the laboratory.

2.5. Acute toxicity studies

An acute toxicity study relating to the determination of median lethal dose (LD₅₀) was performed by the method of Lorke[9]. Mice were randomly divided into EASM-treated 'test' groups and vehicle-treated 'control' group consisting of 7 groups with 5 mice per cage. EASM (100, 200, 400, 800, 1600, and 3200 mg/kg) was separately administered intraperitoneally to the mice in each of the test groups. Each mouse in the control group was treated with vehicle alone [2% dimethylsulfoxide (DMSO)]. Then after 24 h, the mortality number caused by the extract was observed from which the LD₅₀ of EASM was determined.

2.6. Cell growth inhibition

In vivo tumour cell growth inhibition was carried out by the method as described by Sur et al.[10]. 2×10⁶ EAC cells were inoculated into 5 groups of mice (6 in each) on day 0. The control group 1 was treated with vehicle (2% DMSO). Mice in group 2, 3 and 4 were administered (ip) with EASM at 50, 100 and 200 mg/kg/day doses and group 5 received bleomycin (0.3 mg/kg/day). Treatment was continued for 5 days and on the 6th day after tumour transplantation, animals were sacrificed. Tumour cells were collected by repeated washing with 0.9% saline and viable tumour cells in the treated groups were compared with those of the control.

2.7. Studies on survival time and hematological parameters

Swiss albino mice were divided into six groups (n = 6). All animals were injected with EAC cells (2×10⁵ cells/mouse) intraperitoneally except for the normal group. This was taken on day 0. Group 1 served as the normal control and group 2 served as the tumour control. These two groups received 2% DMSO. Group 3, 4 and 5 were treated with EASM at 50, 100 and 200 mg/kg bw, respectively. Group 6 which served as the positive control was treated with bleomycin at 0.3 mg/kg bw. All these treatments were given 24 h after the tumour inoculation, once daily for 10 days. On the 14th day after tumour inoculation, hematological parameters (hemoglobin, RBC, WBC and differential count of WBC) were measured from freely flowing tail vein blood of each mice of each group under sterile condition[11]. Then mean survival time (MST) of each EAC cell inoculated group was noted.

2.8. Statistical analysis

All values were expressed as mean±SEM (Standard Error of Mean). Statistical analysis was performed with one way analysis of variance (ANOVA) followed by Dunnett’s t’ test using SPSS statistical software of 14 version. P<0.05 was considered to be statistically significant when compared with control.

3. Results

The LD₅₀ value of EASM was evaluated in Swiss albino mice and found to be 3 025 mg/kg bw. Antitumour activity of EASM against EAC cell bearing mice was assessed by the parameters such as viable EAC cell (% inhibition in cell growth), mean survival time (MST), percentage (%) increase of life span (% ILS) and body weight gain. The average number of viable tumour cells per mouse of tumour control group was found to be (5.73±0.95)×10⁶ cells/mL. Treatment with EASM (50, 100 and 200 mg/kg) reduced the viable cells significantly (P<0.05) (Figure 1A).

The effect of EASM on the survival of EAC bearing mice was shown in Figure 1B. The MST of the control group was (20.80±0.73) days, whereas it was (28.43±2.10), (22.80±1.46), (33.00±1.78) and (40.20±2.25) for the groups treated with EASM (50, 100 and 200 mg/kg) and bleomycin (0.3 mg/kg), respectively. The increase in the life span of EAC cell bearing mice treated with EASM (50, 100 and 200 mg/kg) and bleomycin (0.3 mg/kg) was found to be 36.5%, 57.6%, 58.7% and 93.2%, respectively (Figure 1C). On the 14th day of tumour cell inoculation, the average weight gain of only
Table 1
Effect of EASM on hematological parameters of EAC cell bearing mice (Mean±SEM) (mg/kg bw).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal</th>
<th>EAC +Vehicle</th>
<th>EAC + EASM (50)</th>
<th>EAC + EASM (100)</th>
<th>EAC + EASM (200)</th>
<th>EAC + Bleomycin (0.3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hgb (g/dL)</td>
<td>15.48±0.22</td>
<td>7.38±0.18*</td>
<td>7.73±0.25*</td>
<td>8.38±0.19*</td>
<td>7.13±0.36*</td>
<td>14.37±0.25*</td>
</tr>
<tr>
<td>RBC (×10^6 cells/mL)</td>
<td>5.67±0.10</td>
<td>2.80±0.27</td>
<td>3.27±0.15*</td>
<td>4.06±0.16*</td>
<td>3.12±0.08*</td>
<td>4.90±0.09*</td>
</tr>
<tr>
<td>WBC (×10^6 cells/mL)</td>
<td>8.75±0.53</td>
<td>15.40±1.19*</td>
<td>13.60±1.47*</td>
<td>11.00±0.78*</td>
<td>12.40±1.05*</td>
<td>9.37±0.59*</td>
</tr>
<tr>
<td>Lymphocytes (g)</td>
<td>75.50±1.36</td>
<td>37.80±1.35*</td>
<td>38.60±1.13*</td>
<td>34.30±1.09</td>
<td>40.30±0.91</td>
<td>68.20±0.90*</td>
</tr>
<tr>
<td>Neutrophils (g)</td>
<td>19.60±1.38</td>
<td>60.70±1.04*</td>
<td>58.20±1.05*</td>
<td>61.70±1.10</td>
<td>55.10±0.72</td>
<td>28.80±0.93*</td>
</tr>
<tr>
<td>Monocytes (g)</td>
<td>1.87±0.40</td>
<td>1.20±0.38</td>
<td>1.65±0.25*</td>
<td>1.75±0.31</td>
<td>1.52±0.26</td>
<td>2.00±0.27</td>
</tr>
</tbody>
</table>

*P<0.05, against normal group; \*P<0.05, against EAC control group.

Figure 1. Effect of EASM on EAC cell bearing mice.
A: Viable EAC cells on the 6th day after tumor cell inoculation; B: Mean survival time; C: % increase in life span; D: Body weight gain on the 14th day. Data are expressed as mean ± SEM (n = 6). *P<0.05, between EAC control and EASM–treated group.

EAC cell bearing mice was (21.74±1.55) g whereas it was (16.57±1.76), (13.48±1.57), (12.86±1.20) and (4.28±1.00) g for the groups treated with EASM (50, 100 and 200 mg/kg) and bleomycin (0.3 mg/kg), respectively. EAMS at 200 mg/kg dose significantly reduced the weight gain (P<0.05).

Hematological parameters of EAC cell bearing mice on the 14th day showed significant changes when compared with normal mice (P<0.05) (Table 1). The total WBC count was found to increase with a reduction in the hemoglobin content and total RBC count. The differential count of WBC showed that the percentage of neutrophils was increased while that of lymphocytes was decreased when compared with normal mice. At the same time interval, treatment of EASM (50, 100 and 200 mg/kg) could change these parameters near to normal. Maximum and significant alteration occurred in the EASM treatment at the dose of 100 mg/kg (P<0.05). The differential counts were found to be similar to that of EAC cell bearing mice and treatment of EASM could not normalize the differential count.

4. Discussion

The results of the present study clearly demonstrate the tumour inhibitory activity of EASM against EAC. The reliable criteria for evaluating an anticancer drug are prolongation of lifespan of the animal and decrease in WBC count of blood. Our results have shown an increase in
The lifespan accompanied by a reduction in WBC count in EASM treated mice. It had significant effect on increasing the life span of ascites tumour bearing animals and also found to reduce the viable EAC cells in animal models. These results clearly demonstrate the antitumour effect of EASM against EAC. During the process of cancer chemotherapy the major problems are myelosuppression and anaemia[12]. The anaemia encountered in tumour bearing mice is mainly due to reduction in RBC and hemoglobin and this may occur either due to iron deficiency or hemolytic or myelopathic conditions[13]. Treatment with EASM restored the hemoglobin content, RBC and WBC cell count to normal values. This indicates that EASM possesses protective effect on the haematopoietic system.

A regular and rapid increase in ascetic fluid volume was observed in EAC bearing mice. Ascetic fluid is the direct nutritional source for tumour growth because it meets the nutritional requirements of tumor cells[14]. EASM treatment reduced the number of viable cancer cell count and increased the lifespan. It may be suggested that EASM can reduce the nutritional fluid volume and thereby arrests tumour growth and increases the life span.

Preliminary phytochemical screening indicated the presence of triterpenoids, flavonoids and glycosides in EASM. These compounds are known to possess potent antitumour properties[15-19]. In addition, flavonoids could also induce mechanisms that may kill cancer cells and inhibit tumor invasion[20,21]. The antitumour properties of EASM may be due to these compounds. Further research work is needed to establish the exact antitumour mechanism action of EASM as well as identify the main active phytochemicals responsible for the inhibition of EAC.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

The authors are thankful to Indian Institute for Chemical Biology (IICB), Kolkata, India for providing Ehrlich ascites carcinoma (EAC) cells to carry out the research.

References